Information  X 
Enter a valid email address

EPIC/TIDM matching '0QLR'

Date
Time Source
Company
Announcement
15 Mar 2021 10:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
09 Mar 2021 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
05 Mar 2021 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces change to the Executive Committee
02 Mar 2021 2:26 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
17 Feb 2021 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
16 Feb 2021 6:22 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Entresto® granted expanded indication in chronic heart failure by FDA
11 Feb 2021 12:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics
26 Jan 2021 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
11 Jan 2021 9:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
18 Dec 2020 9:50 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives complete response letter from U.S. FDA for inclisiran
16 Dec 2020 12:17 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
14 Dec 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
09 Dec 2020 2:45 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer
  2:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
08 Dec 2020 3:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
05 Dec 2020 3:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas
04 Dec 2020 5:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
24 Nov 2020 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event
19 Nov 2020 9:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
  2:43 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
  6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis set to achieve 100% renewable electricity in its European operations
13 Nov 2020 3:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender
06 Nov 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
05 Nov 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
02 Nov 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention
30 Oct 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia
28 Oct 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
27 Oct 2020 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.
26 Oct 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)
16 Oct 2020 12:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
01 Oct 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement
23 Sep 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
19 Sep 2020 3:25 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation
  3:20 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma
16 Sep 2020 10:02 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM
  3:24 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond
14 Sep 2020 11:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) European Medicines Agency (EMA) approves safety label update for Novartis Beovu®
  6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
11 Sep 2020 4:05 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)
  4:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
08 Sep 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum
07 Sep 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
01 Sep 2020 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality
30 Aug 2020 7:30 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
29 Aug 2020 11:30 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)
26 Aug 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
22 Aug 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma
20 Aug 2020 6:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
17 Aug 2020 6:11 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces US District Court for the District of Delaware upholds validity of Gilenya® (fingolimod) dosage regimen patent
05 Aug 2020 10:01 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
04 Aug 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
03 Aug 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis
27 Jul 2020 8:29 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe
24 Jul 2020 12:36 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease
21 Jul 2020 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.
16 Jul 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
07 Jul 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
01 Jul 2020 5:13 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case
29 Jun 2020 7:45 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
26 Jun 2020 12:37 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile


Company Announcements Archive »


a d v e r t i s e m e n t